Addex Therapeutics annual free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
Addex Therapeutics Free Cash Flow (FCF) History (ADXN)
Addex Therapeutics reported −CHF5.4M in free cash flow for fiscal 2024, an increase of CHF2.6M from the previous fiscal year, with a free cash flow margin of −1330.07%.
View full Addex Therapeutics company overviewAddex Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −CHF5.4M | CHF2.6M | — | −1330.07% |
| 2023 | 2023-12-31 | −CHF8.0M | CHF8.4M | — | −495.94% |
| 2022 | 2022-12-31 | −CHF16.4M | −CHF1.7M | — | −1155.61% |
| 2021 | 2021-12-31 | −CHF14.7M | −CHF2.5M | — | −505.32% |
| 2020 | 2020-12-31 | −CHF12.2M | −CHF2.7M | — | −338.78% |
| 2019 | 2019-12-31 | −CHF9.5M | −CHF11.3M | — | −344.23% |
| 2018 | 2018-12-31 | CHF1.7M | CHF3.9M | — | +28.83% |
| 2017 | 2017-12-31 | −CHF2.1M | — | — | −428.19% |
Addex Therapeutics quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Addex Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −CHF9.5M to −CHF5.4M, a net increase of CHF4.1M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Addex Therapeutics filings at SEC.gov ↗